Evidence map›Paper›PMID 40427122›Full record

ArticleCancers2025

Neurotrophins as Potential Biomarkers for Active Disease and Poor Outcome in Pediatric Acute Lymphoblastic Leukemia.

Karine Pereira de Andrade, Gustavo Lovatto Michaelsen, Lívia Fratini Dutra, Rebeca Ferreira Marques, Daniela Elaine Roth Benincasa, Júlia Plentz Portich, Jiseh Fagundes Loss, Lauro José Gregianin, André Tesainer Brunetto, Marialva Sinigaglia and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Karine Pereira de AndradeCancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.
Gustavo Lovatto MichaelsenChildren's Cancer Institute, Porto Alegre 90620-110, RS, Brazil.
Lívia Fratini DutraCancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.ORCID 0000-0003-1592-0830
Rebeca Ferreira MarquesCancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.
Daniela Elaine Roth BenincasaPediatric Oncology Service, Conceição Children Hospital, Porto Alegre 91350-250, RS, Brazil.
Júlia Plentz PortichCancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.ORCID 0000-0002-4633-2903
Jiseh Fagundes LossPediatric Oncology Service, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.
Lauro José GregianinPediatric Oncology Service, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.ORCID 0000-0003-0788-7858
André Tesainer BrunettoChildren's Cancer Institute, Porto Alegre 90620-110, RS, Brazil.ORCID 0000-0002-7958-1279
Marialva SinigagliaChildren's Cancer Institute, Porto Alegre 90620-110, RS, Brazil.ORCID 0000-0002-8324-6860
Rafael RoeslerCancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.ORCID 0000-0001-6016-2261
Mariane da Cunha JaegerCancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.
Marcelo LandNational Institute of Science and Technology in Childhood Cancer Biology and Pediatric Oncology-INCT BioOncoPed, Porto Alegre 90050-170, RS, Brazil.
Caroline Brunetto de FariasCancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre's Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.

Funding

Hospital de Clínicas de Porto Alegre 2019-0695INCT Biooncoped 406484/2022-8Instituto do Câncer Infantil Not applicable
6 · The paper itself

Abstract

backgroundNeurotrophins (NTs) are pivotal growth factors in cellular development and survival. Their precise implications in Acute Lymphoblastic Leukemia (ALL) remain unclear.

methodsPediatric ALL samples (2011-2021) were analyzed from a Southern Brazil cohort. Neurotrophin levels were quantified via ELISA, with survival analysis using Kaplan-Meier curves. Gene expression data were sourced from public genomic repositories and analyzed with R software version 4.0.5.

resultsAt diagnosis, pro-BDNF, BDNF, and NGF levels were significantly lower than in healthy controls. Reduced pro-BDNF correlated with unfavorable outcomes. NGF and sortilin were highly expressed in healthy samples, while BDNF and p75

conclusionsNeurotrophins show significant alterations in the tumor microenvironment of pediatric ALL. Further studies are needed to elucidate their precise role and prognostic potential.

Indexed as

ALLBDNFchildhood leukemianeurotrophinsprognosis

Identifiers

PMID40427122
PMCPMC12110685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.